Skip to Content

'
Charlotte C. Sun, Dr.P.H., M.P.H.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Adjunct Assistant Professor, Management and Policy Sciences, The University of Texas School of Public Health, Houston, TX

Bio Statement

Dr. Sun joined the faculty as a Research Instructor in 2001.  Dr. Sun’s research interests include developing methods to improve and better understand the process of the patient-physician making for women who have been diagnosed with or at risk for developing gynecologic malignancies, as well as evaluating prognostic factors for survival in women with borderline and low grade serous tumors of the ovary.  Dr. Sun’s research efforts have included the assessment of treatment preferences and quality of life issues for women with ovarian and cervix cancer, as well as preferences for prophylactic surgery for women with inherited cancer syndromes.  

Dr. Sun is a member of the American Society of Clinical Oncology, the Multinational Association of Supportive Care in Cancer, the Society of Medical Decision Making, and the American Public Health Association.

Office Address

The University of Texas MD Anderson Cancer Center
1155 Herman Pressler, Unit 1362
Unit Number: Unit 1362
Houston, TX 77030
Room Number: CPB6.3244
Phone: (713) 745-4580
Fax: (713) 792-7586
Email: ccsun@mdanderson.org

Education & Training

Degree-Granting Education

1988 Rice University, Houston, Houston, TX, BA, Biochemistry and Environmental Engineering

Postgraduate Training

1/1994-5/2001 Doctor of Public Health – Health Services Organization, Health Services, The University of Texas School of Public Health, Houston, TX, David Lairson, Ph.D.
9/1992-6/1993 Master’s of Public Health – Health Services, Health Services, Boston University School of Public Health, Boston, MA

Experience/Service

Academic Appointments

Special Faculty Member, University of Texas Graduate School of Biomedical Sciences, Houston, TX, 2005-2009
Assistant Professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, 9/2004-2010
Adjunct Instructor, Management and Policy Sciences, The University of Texas School of Public Health, Houston, TX, 2003-2005
Instructor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2001-2004
Senior Research Assistant, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1/1999-2001
Graduate Research Assistant, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1/1997-1/1999
Graduate Research Assistant, Department of Medical Specialties, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1/1995-1/1997

Institutional Committee Activities

Vice-Chair, IRB4 - Institutional Review Board 4, 8/2010-present
Member, MDACC Survivorship Research Group - Outcomes and Health disparities Research Team, 1/2007-present
Vice-Chair, IRB4 Institutional Review Board for Psychosocial, Behavioral & Health Services Research, 2007-present
Vice-Chair, Health Services Research Working Group, 2006-present
Member, Clinical Research Impact Committee, 2006-present
Member, Protocol Review Monitoring committee, 2006-2008
Member, Institutional Review Board for Psychosocial, Behavioral & Health Services Research (IRB 4), 1/2005-present
Member, Health Services/Psychosocial/Behavioral Working Group, 1/2005-present
Co-Chair, Psychosocial, Behavioral & Health Services Research Committee, 2005-2008
Member, Low Grade Serous Tumor Study Group, 2002-present
Member, Psychosocial, Behavioral & Health Services Research Committee, 1/2001-1/2003
Member, Executive Committee, 1/2000
Volunteer, Blanton-Davis Ovarian Cancer Research Program Sprint for Life, 1/1999-present

Honors and Awards

2002 2nd place poster award at the 3rd Annual Houston Area Health Services & Outcomes Research Conference, November 25, 2002, Houston, Texas, Kelsey Research Foundation.
2001 Delta Omega – Alpha Iota Chapter Honorary Public Health Society
2000 Lamb Scholarship Award for Health Services Organization
1997-1998 Lamb Scholarship

Selected Publications

Peer-Reviewed Original Research Articles

1. Brandt AC, Tschirgi ML, Ready KJ, Sun C, Darilek S, Hecht J, Arun BK, Lu KH. Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes. Fam Cancer 9(3):479-87, 9/2010. e-Pub 4/30/2010. PMID: 20431955.
2. Ready KJ, Daniels MS, Sun CC, Peterson SK, Northrup H, Lu KH. Obstetrics/Gynecology Residents' Knowledge of Hereditary Breast and Ovarian Cancer and Lynch Syndrome. J Cancer Educ Epub ahead of print(3):401-4, 9/2010. e-Pub 2/26/2010. PMID: 20186516.
3. Wong KK, Tsang YTM, Deavers MT, Mok SC, Zu Z, Sun CC, Malpica A, Wolf JK, Lu KH, Gershenson DM,. BRAF Mutation is rare in Advanced Stage Low-Grade Ovarian Serous Carcinomas. The American Journal of Pathology 177(4). e-Pub 8/2010. PMID: 20802181.
4. Schmeler KM, Tao X, Frumovitz M, Deavers MT, Sun CC, Sood AK, Brown J, Gershenson DM, Ramirez PT. Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol 116(2 Pt 1):269-73, 8/2010. PMID: 20664385.
5. Schmeler KM, Jhingran A, Iyer RB, Sun CC, Eifel PJ, Soliman PT, Ramirez PT, Frumovitz M, Bodurka DC, Sood AK. Pelvic fractures after radiotherapy for cervical cancer: implications for Survivors. Cancer 116(3):625-30, 2/1/2010. PMID: 20052724.
6. Kwon JS, Daniels MS, Sun CC, Lu KH. Preventing future cancers by testing women with ovarian cancer for BRCA mutations. J Clin Oncol Epub ahead of print(4):675-82, 2/1/2010. e-Pub 10/19/2009. PMID: 19841329.
7. Tung CS, Sun CC, Schlumbrecht MP, Meyer LA, Bodurka DC. Survival after intestinal perforation: can it be predicted? Gynecol Oncol 115(3):349-53, 12/2009. e-Pub 9/18/2009. PMID: 19765809.
8. Frumovitz M, Sun CC, Schmeler KM, Deavers MT, Dos Reis R, Levenback CF, Ramirez PT. Parametrial Involvement in Radical Hysterectomy Specimens for Women With Early-Stage Cervical Cancer. Obstet Gynecol 114(1):93-99, 7/2009. PMID: 19546764.
9. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 114(1):48-52, 7/2009. e-Pub 4/10/2009. PMID: 19361839.
10. Ramondetta LM, Johnson AJ, Sun CC, Atkinson N, Smith JA, Jung MS, Broaddus R, Iyer RB, Burke T. Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer 115(9):1867-74, 5/1/2009. PMID: 19241422.
11. Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, Lu KH, Hortobagyi GN, Arun BK. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115(8):1598-604, 4/15/2009. PMCID: PMC2680417.
12. Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 16(4):836-47, 4/2009. e-Pub 2/5/2009. PMCID: PMC3066077.
13. Frumovitz M, Sun CC, Jhingran A, Schmeler KM, Dos Reis R, Milam MR, Soliman PT, Taylor K, Ramirez PT. Radical hysterectomy in obese and morbidly obese women with cervical cancer. Obstet Gynecol 112(4):899-905, 10/2008. PMID: 18827134.
14. Kwon JS, Sun CC, Peterson SK, White KG, Daniels MS, Boyd-Rogers SG, Lu KH. Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. Cancer 113(2):326-35, 7/15/2008. PMID: 18506736.
15. Varadhachary GR, Wolff RA, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Abdalla E, Wang H, Staerkel GA, Lee JH, Ross WA, Tamm EP, Bhosale PR, Krishnan S, Das P, Ho L, Xiong H, Abbruzzese JL, Evans DB. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26(21):3487-95, 7/20/2008. PMID: 18640929.
16. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26(21):3496-502, 7/20/2008. PMID: 18640930.
17. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA, Varadhachary GR, Hwang RF. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206(5). e-Pub 3/17/2008. PMID: 18471707.
18. Jones KL, Saucier JM, Sun CC, Bevers MW, Ramondetta LM, Brown J, Smith JA. Comparison of chemotherapy education and patient preferences in community versus academic gynecology oncology clinics. J Oncol Pharm Pract 14(1):31-6, 3/2008. PMID: 18337438.
19. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, Ramirez PT, Gershenson DM. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 108(3):510-4, 3/2008. e-Pub 12/26/2007. PMID: 18155273.
20. Westin SN, Bustillos D, Gano JB, Fields MM, Coker AL, Sun CC, Ramondetta LM. Social factors affecting treatment of cervical cancer: ethical issues and policy implications. Obstet Gynecol 111(3):747-51, 3/2008. PMID: 18310380.
21. Du XL. Sun CC. Milam MR. Bodurka DC. Fang S. Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. International Journal of Gynecological Cancer 18(4):660-669, 2008.
22. Lu KH, Schorge JO, Rodabaugh KJ, Daniels MS, Sun CC, Soliman PT, White KG, Luthra R, Gershenson DM, Broaddus RR. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol 25(33). e-Pub 10/9/2007. PMID: 17925543.
23. Frumovitz M, dos Reis R, Sun CC, Milam MR, Bevers MW, Brown J, Slomovitz BM, Ramirez PT. Comparison of total laparoscopic and abdominal radical hysterectomy for patients with early-stage cervical cancer. Obstet Gynecol 110(1):96-102, 7/2007. PMID: 17601902.
24. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, Hwang R, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 246(1):52-60, 7/2007. PMCID: PMC1899216.
25. Shvartsman HS, Sun CC, Bodurka DC, Mahajan V, Crispens M, Lu KH, Deavers MT, Malpica A, Silva EG, Gershenson DM. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. Gynecol Oncol 105(3):625-9, 6/2007. e-Pub 2/22/2007. PMID: 17320156.
26. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 105(2):404-8, 5/2007. e-Pub 2/9/2007. PMID: 17292461.
27. dos Reis R. Frumovitz M. Milam MR. Capp E. Sun CC. Coleman RL. Ramirez PT. Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis. Gynecologic Oncology 107(3):458-463, 2007.
28. Tseng JF. Pisters PW. Lee JE. Wang H. Gomez HF. Sun CC. Evans DB. The learning curve in pancreatic surgery. Surgery 141(5):694-701, 2007.
29. Slomovitz BM, Sun CC, Frumovitz M, Soliman PT, Schmeler KM, Pearson HC, Berenson A, Ramirez PT, Lu KH, Bodurka DC. Are women ready for the HPV vaccine? Gynecol Oncol 103(1):151-4, 10/2006. e-Pub 3/21/2006. PMID: 16551476.
30. Wolf JK, Bodurka DC, Verschraegen C, Sun CC, Branham D, Jenkins AD, Atkinson N, Gershenson DM. A Phase II trial of oral capecitabine in patients with platinum - and taxane - refractory ovarian, fallopian tube, or peritoneal cancer. Gynecol Oncol 102(3):468-74, 9/2006. e-Pub 3/3/2006. PMID: 16516276.
31. Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, Erlichman JL, Arun BK, Daniels MS, Rimes SA, Peterson SK, Slomovitz BM, Milam MR, Gershenson DM, Lu KH. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol 108(3 Pt 1):515-20, 9/2006. PMID: 16946209.
32. Schmandt RE, Bennett M, Clifford S, Thornton A, Jiang F, Broaddus RR, Sun CC, Lu KH, Sood AK, Gershenson DM. The BRK Tyrosine Kinase is Expressed in High-Grade Serous Carcinoma of the Ovary. Cancer Biol Ther 5(9):1136-41, 9/2006. PMID: 16855388.
33. Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 108(2):361-8, 8/2006. PMID: 16880307.
34. Elting LS, Cooksley C, Bekele BN, Frumovitz M, Avritscher EB, Sun C, Bodurka DC. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer 106(11):2452-8, 6/2006. PMID: 16639738.
35. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, Daniels MS, White KG, Boyd-Rogers SG, Conrad PG, Yang KY, Rubin MM, Sun CC, Slomovitz BM, Gershenson DM, Lu KH. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354(3):261-9, 1/2006. PMID: 16421367.
36. Ramondetta LM. Sun C. Hollier L. Jarrett L. Folloder J. Tortolero-Luna G. Hughes A. Jhingran A. Brown J. Advanced cervical cancer treatment in Harris County: pilot evaluation of factors that prevent optimal therapy. Gynecologic Oncology 103(2):547-553, 2006.
37. Zighelboim I. Ramirez PT. Gao F. Slomovitz BM. Sun C. Frumovitz M. Jhingran A. Levenback C. Retroperitoneal lymph node resection in patients with cervical cancer. Surgical Oncology 15(2):79-83, 2006.
38. Schmeler KM, Soliman PT, Sun CC, Slomovitz BM, Gershenson DM, Lu KH. Endometrial cancer in young, normal-weight women. Gynecol Oncol 99(2):388-92, 11/2005. e-Pub 7/26/2005. PMID: 16051336.
39. Frumovitz M, Sun CC, Schover LR, Munsell MF, Jhingran A, Wharton JT, Eifel P, Bevers TB, Levenback CF, Gershenson DM, Bodurka DC. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol 23(30):7428-36, 10/2005. PMID: 16234510.
40. Tangjitgamol S, Ramirez PT, Sun CC, See HT, Jhingran A, Kavanagh JJ, Deavers MT. Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study. Int J Gynecol Cancer 15(4):646-56, Jul-Aug, 7/2005. PMID: 16014119.
41. Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13(4):219-27, 4/2005. e-Pub 11/9/2004. PMID: 15538640.
42. Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, Burke TW, Lu KH. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol 105(3):575-80, 3/2005. PMID: 15738027.
43. Lu KH, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, Bandipalliam P, Chen L, Allen B, Conrad P, Terdiman J, Sun C, Daniels M, Burke T, Gershenson DM, Lynch H, Lynch P, Broaddus RR. Gynecologic Malignancy as a “Sentinel Cancer” for Women with HNPCC. Obstetrics & Gynecology 105(3):569-74, 2005.
44. Ramirez PT, Sun CC, Vidal CI, Schimp V, Slomovitz BM, Bevers MW, Bodurka DC. Outcomes of hysteroscopy and hysterectomy in breast cancer patients. Cancer Therapy:in press, 2005.
45. Ramondetta LM, Jenkins AD, Sun CC, Johnston T, Wolf JK, Bodurka DC, Brown J, Atkinson EN, Levenback C. Phase II Trial of Capecitabine in Recurrent Squamous Cell Carcinoma of the Cervix. Gynecol Oncol 97(3):840-844, 2005. PMID: 15882895.
46. Tseng JF, Raut CP, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Gomez HF, Sun CC, Crane CH, Wolff RA, Evans DB. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 8(8):935-49; discussion 949-50, 12/2004. PMID: 15585381.
47. Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 95(1):133-8, 10/2004. PMID: 15385122.
48. Tseng JF, Kronowitz SJ, Sun CC, Perry AC, Hunt KK, Babiera GV, Newman LA, Singletary SE, Mirza NQ, Ames FC, Meric-Bernstam F, Ross MI, Feig BW, Robb GL, Kuerer HM. The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer. Cancer 101(7):1514-23, 10/2004. PMID: 15378473.
49. Frumovitz M, Slomovitz BM, Singh DK, Broaddus RR, Abrams J, Sun CC, Bevers M, Bodurka DC. Frozen section analyses as predictors of lymphatic spread in patients with early-stage uterine cancer. J Am Coll Surg 199(3):388-93, 9/2004. PMID: 15325608.
50. Slomovitz BM, Sun CC, Ramirez PT, Bodurka DC, Diaz P, Lu KH. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? Obstet Gynecol 104(2):255-60, 8/2004. PMID: 15291996.
51. Smith JA, Kindo CC, Kurian S, Whitaker LM, Burke C, Wachel B, Sun CC, Weaver CL, Danielson MG, Fitzgerald MA, Munsell M, Zandstra FA, Bodurka DC. Evaluation of patient chemotherapy education in a gynecology oncology center. Support Care Cancer 12(8):577-83, 8/2004. e-Pub 5/28/2004. PMID: 15168104.
52. Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 22(15):3126-32, 8/2004. PMID: 15284264.
53. Soliman PT, Slomovitz BM, Broaddus RR, Sun CC, Oh JC, Eifel PJ, Gershenson DM, Lu KH. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol 94(2):456-62, 8/2004. PMID: 15297188.
54. Schimp VL, Worley C, Brunello S, Levenback CC, Wolf JK, Sun CC, Bodurka DC, Ramirez PT. Vacuum-assisted closure in the treatment of gynecologic oncology wound failures. Gynecol Oncol 92(2):586-91, 2/2004. PMID: 14766251.
55. Schmandt RE, Broaddus R, Lu KH, Shvartsman H, Thornton A, Malpica A, Sun C, Bodurka DC, Gershenson DM. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 98(4):758-64, 8/15/2003. PMID: 12910520.
56. Sun CC, Bodurka DC, Donato ML, Rubenstein EB, Borden CL, Basen-Engquist K, Munsell MF, Kavanagh JJ, Gershenson DM. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol Oncol 87(1):118-28, 10/2002. PMID: 12468352.
57. Robinson JB, Sun CC, Bodurka-Bevers D, Im DD, Rosenshein NB. Cavitational ultrasonic surgical aspiration for the treatment of vaginal intraepithelial neoplasia. Gynecol Oncol 78(2):235-41, 8/2000. PMID: 10926809.
58. Bodurka-Bevers D, Sun CC, Gershenson DM. Pharmacoeconomic considerations in treating ovarian cancer. Pharmacoeconomics 17(2):133-50, 2/2000. PMID: 10947337.
59. Cantor SB, Sun CC, Tortolero-Luna G, Richards-Kortum R, Follen M. A comparison of C/B ratios from studies using receiver operating characteristic curve analysis. J Clin Epidemiol 52(9):885-92, 9/1999. PMID: 10529029.
60. Cantor SB, Mitchell MF, Tortolero-Luna G, Bratka CS, Bodurka DC, Richards-Kortum R. Cost-effectiveness analysis of diagnosis and management of cervical squamous intraepithelial lesions. Obstet Gynecol 91(2):270-7, 2/1998. PMID: 9469288.

Invited Articles

1. Sun CC, Ramirez PT, Bodurka DC. Quality of life for patients with epithelial ovarian cancer. Nat Clin Pract Oncol 4(1):18-29, 1/2007. PMID: 17183353.
2. Bodurka DC, Sun CC, Gerhsenson DM. Review on, "Reproductive issues in the gynecologic cancer patient" Carter J, et al. Oncology 21(5):598-609, 2007.
3. Bodurka DC, Sun CC. Sexual function after gynecologic cancer. Obstet Gynecol Clin North Am 33(4):621-630, 12/2006. PMID: 17116505.
4. Sun CC, Frumovitz M, Bodurka DC. Quality of life and gynecologic malignancies. Curr Oncol Rep 7(6):459-65, 11/2005. PMID: 16221383.
5. Bodurka-Bevers D, Sun CC, Gershenson DM. Economic issues related to ovarian cancer. Oncology Economics 1(9):40-47, 2000.

Editorials

1. Bodurka DC, Sun CC, Frumovitz MMF. Quality of life in cervix cancer survivors – What matters the most in the long-term? Gynecologic Oncology 97:307-309, 2005.
Other Articles
1. Sun CC. The University of Texas M.D. Anderson Cancer Center, Preference Assessment Inventory (P.A.I.), U.S., copyright, 2003.

Abstracts

1. Cantor SB, Bratka CS, Richards-Kortum R, Mitchell MF. A ‘league table’ for receiver operating characteristic curve analysis? . Medical Decision Making 16:466, 1996.
2. Cantor SB, Rubenstein EB, Elting LS, Frisbee-Hume S, Bratka CS, Stedman D, Rolston KVI. Economic Evaluation of Management Strategies for Low-Risk Febrile Neutropenic Cancer Patients. Program/Proceedings of the American Society of Clinical Oncology 16:419a, 1997.
3. Bratka CS, Elting L, Martin C, Chau Q, Rubenstein EB. Patients’ Ratings of Illness and Stability, Correlation with Clinicians’ Ratings and Emergency Center Outcomes. Supportive Care in Cancer 5(2):173, 1997.
4. Bratka C, Rubenstein E, Martin C, Chau Q, Elting L. Predicting Emergency Center (EC) Outcomes For Cancer Patients (pts). Program/Proceedings of the American Society of Clinical Oncology 16:422a, 1997.
5. Sun CC, Bodurka-Bevers D, Borden CL, Cantor SB, Rieger PT, Mills GB, Gershenson DM, Lairson DR. Do Preferences Vary By Method of Preference Assessment or Patient Group?. Medical Decision Making 20(4):482, 2000.
6. Sun CC, Bodurka-Bevers DC, Rieger P, Martin CG, Mills GB, Gershenson DM, Cantor SB. Patient Preferences for Outcomes in Women at High-Risk for Breast/Ovarian Cancer – Who and How You Ask Matters. Program/Proceedings of the American Society of Clinical Oncology 19:435a, 2000.
7. Bodurka-Bevers, DC, Sun CC, Cantor SB, Rieger P, Martin CG, Mills GB, Gershenson DM. Preferences Over Time of Women at High-Risk of Breast/Ovarian Cancer Who Undergo Genetic Counseling/Ovarian Cancer Screening. Program/Proceedings of the American Society of Clinical Oncology 19:444a, 2000.
8. Sun CC, Bodurka-Bevers D, Cantor SB, Gershenson DM, Lairson D. Preferences Using Standard Gamble and Time Trade-off: Societal versus Patient Perspectives. Association for Health Services Research Annual Meeting CD-ROM Conference Proceedings:Abstract #93, 2000.
9. Sun CC, Bodurka-Bevers, D, Borden CL, Rojas MS, Lerten F, Goldstein S, Gershenson DM, Morris M. A Pilot Study to Assess Patient Preferences for Side Effects of Chemoradiation. Gynecologic Oncology 80(2):288, 2001.
10. Sun CC, Bodurka-Bevers, Gershenson DM, Lairson DL. Estimating Quality-Adjusted Survival For Women at High-Risk for Developing Breast Cancer: A Monte Carlo Markov Model Incorporating 3 Different Sets of Preferences. Academy for Health Services Research and Health Policy Annual Meeting CD-ROM Conference Proceedings:Abstract #67, 2001.
11. Sun CC, Donato ML, Cooke S, Borden CL, Basen-Engquist K, Fitzgerald MA, Kavanagh JJ, Gershenson DM, Bodurka-Bevers D ;. Ovarian Cancer (OVCA) Patients (PTS) Undergoing High-Dose Chemotherapy (HDCT) With Peripheral Blood Stem Cell Support (PBSCS): Preferences For Toxicities Over Time. Programs/Proceedings of the American Society for Clinical Oncology, 37th Annual Meeting.:Publication # 2576, 2001.
12. Sun CC, Borden CL, Young VN, Charneco L, Rojas M, Lerten F, Goldstein S, Morris M, Gershenson DM, Bodurka DC. A feasibility study of assessing patient preferences and quality of life in culturally-diverse women with cervix cancer. Academy for Health Services Research and Health Policy Annual Meeting, CD-ROM Conference Proceedings. Part 1 1:48, 6/2002.
13. Wolf JK, Sun CC, Verschraegen CF, Jenkins AD, Branham DW, Bodurka DC. A phase II study of Xeloda in patients with chemotherapy resistant recurrent ovarian cancers. Programs/Proceedings of the American Society for Clinical Oncology, 38th Annual Meeting. Publication number 893 21(1), 2002.
14. Sun CC, Borden CL, Charneco L, Young VN, Rojas M, Lerten F, Goldstein S, Morris M, Gershenson DM, Bodurka DC. Chemoradiation for cervix cancer: cultural differences in preferences for side-effects. Programs/Proceedings of the American Society for Clinical Oncology, 38th Annual Meeting. Publication number 2599 21(2), 2002.
15. Sun CC, Bodurka DC, Donato ML, Borden C, Rubenstein EB. Nausea and vomiting side-effects of cancer therapies: preference assessments from patients, health care providers and healthy women. Supportive Care in Cancer 10(4):378, 2002.
16. Anderson ML, Bodurka DC, White K, Sun CC, Wolf JK, Burke TW. Outcome of patients undergoing surgical resection of recurrent leiomyosarcoma. Gynecologic Oncology 84(3):528, 2002.
17. Sun CC, Borden CL, Donato ML, Cooke S, Basen-Engquist K, Fitzgerald MA, Kavanagh JJ, Gershenson DM, Bodurka DC. Patient preferences for side-effects of chemotherapy for ovarian cancer: do preferences change over time? . Gynecologic Oncology 84(3):493, 2002.
18. Sun CC, Bodurka DC, Rubenstein EB, Borden CL, Basen-Engquist K, Munsell MF, Kavanagh JJ, Gershenson DM. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time?. 3rd Annual Kelsey Research Foundation's Health Services and Outcomes Research Conference, 2002.
19. Weaver C, Sun CC, Schover LR, Aday L, Bodurka DC. Assessment of quality of life and sexual activity after treatment for cervix cancer. AcademyHealth 20th Annual Research Meeting, CD-ROM Conference Proceedings:43, 6/2003.
20. Lu K, Beahm E, Arun B, Bodurka-Bevers D, Sun C, Miller M, Hunt K, Ames F, Strong L, Meric-Bernstam, F. Coordinated Prophylactic Surgical Management for Women with Breast-Ovarian Cancer Syndrome. Proceedings of the 2nd Annual International Conference on Frontiers in Cancer Prevention Research:100 (# C190), 2003.
21. Frumovitz M, Ramirez PT, Tortolero-Luna G, Bodurka DC, Sun C, Malpica A, Levenback C. Groin recurrence in patients who underwent lymphatic mapping for vulvar malignancy. Int J Gyn Cancer 13(Supp 1):17, 2003.
22. Ramirez PT, Vidal C, Schimp VL, Sun CC, Slomovitz BM, Bevers MW, Bodurka DC. Indications and Outcomes of Hysteroscopy and Hysterectomy in Breast Cancer Patients. Gynecologic Oncology 88(2):216, 2003.
23. Sun CC, Bodurka DC, Weaver C, Andersen R, Gershenson DM, Bast RC. Knowledge of ovarian cancer screening in a low-risk population. AcademyHealth 20th Annual Research Meeting, CD-ROM Conference Proceedings:39, 2003.
24. Bodurka DC, Frumovitz M, Sun CC, Ramirez PT, Bevers MW, Gershenson DM. Laparoscopy For Probable Ovarian Cancer: Less May Not Be More. Gynecologic Oncology 88(2):244, 2003.
25. Bodurka DC, Sun CC, Weaver CB, Jennings J, Melancon CH, Bevers MW, Wolf JW, Ramirez PT, Gershenson DM, Lairson DR. Ovarian cancer (OV CA): The cost of caregiving. Meeting Proceedings of the American Society for Clinical Oncology, 39th Annual Meeting 22:527, 2003.
26. Sun CC, Bodurka DC, Lu KH, Efron B, Andersen A, Bevers TBB, Gershenson DM, Bast RC. Perceptions of OVCA Risk and Screening: Differences between women with a history of breast cancer (WHxBr) and women with no history of breast cancer (WnoBr). Gynecologic Oncology 88(2):239-240, 2003.
27. Sun CC, Slomovitz BM, Frumovitz M, Weaver CB, Lu KH, Gershenson, DM, Bodurka DC. Preference (utility) assessment in patients with gynecologic malignancies: The M. D. Anderson Experience. European Journal of Cancer Supplements 1(3):S16, 2003.
28. Sun CC, Bodurka DC, Weaver CB, Fitzgerald MA, Wolf JK, Levenback C, Kavanagh JJ, Palmer L, Gershenson DM, Rubenstein EB. Preferences (PREF) for Side Effects (SEs) of Chemotherapy (CHEMO): How Long is Too Long and How Much is Too Much? . Meeting Proceedings of the American Society for Clinical Oncology, 39th Annual Meeting 22:743, 2003.
29. Schimp VL, Sun CC, Wolf JK, Bodurka DC, Levenback CL, Ramirez PT. Vacuum-Assisted Closure in the Treatment of Gynecologic Oncology Wound Failures. Gynecologic Oncology 88(2):203-204, 2003.
30. Jenkins AD, Ramondetta L, Johnston T, Sun CC, Wolf JK, Bodurka DC, Atkinson EN, Levenback CF. A Phase II Study of Capecitabine in Recurrent Squamous Cell Carcinoma of the Cervix. Gynecologic Oncology 92:427, 2004.
31. Jhingran A, Bodurka DC, Sun CC, Eifel PJ. Acute toxicity of chemoradiation for cervical cancer. American Radium Society, Napa Valley, CA, 2004.
32. Schimp VL, Sun CC, Jennings J, Soliman P, Bodurka DC. Bowel Obstruction in Ovarian Cancer Patients: Surgical versus Medical Therapy. Gynecologic Oncology 92:453, 2004.
33. Slomovitz BM, Wu W, Soliman PT, Broaddus RR, Sun CC, Bodurka DC, Gershenson DM, Lu KH. Clinical and molecular characteristics of patients who develop breast cancer and uterine papillary serous carcinoma (UPSC). Gynecologic Oncology 92:423-424, 2004.
34. Shvartsman HS, Bodurka D, Sun C, Crispens M, Lu K, Silva E, Gershenson D. Comparative study of disease process and survival in patients with recurrent serous low malignant potential tumor of ovary versus patients with low grade serous carcinoma of the ovary. Meeting Proceedings of the American Society for Clinical Oncology, 39th Annual Meeting 22:452, 2004.
35. Slomovitz BM, Ramirez PT, Bodurka DC, Sun CC, Oh JC, Diaz P, Broaddus RR, Soliman PT, Gershenson DM, Lu KH. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? . Gynecologic Oncology 92:404-405, 2004.
36. Soliman PT, Slomovitz BM, Sun CC, Gershenson DM, Lu KH. Endometrial cancer screening should be considered in women with colon cancer and one family member with an HNPCC-associated Cancer. Gynecologic Oncology 92:434, 2004.
37. Frumovitz M, Slomovitz BM, Broaddus RR, Abrams J, Sun CC, Bevers M, Bodurka DC. Endometrial cancer: To stage or not to stage, part II. Gynecologic Oncology 92:487, 2004.
38. Tangjitgamol S, Ramirez PT, Sun CC, See HT, Jhingran A, Kavanagh JJ, Deavers MT. Expression of HER-2/NEU, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progresterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study. International Gynecologic Cancer Society:222, 2004.
39. Slomovitz BM, Broaddus RR, Sneige N, Tarco E, Soliman PT, Wu W, Sun CC, Schmandt R, Burke TW, Gershenson DM, Lu KH. Her-2/neuexpression and amplification in uterine papillary serous carcinoma (UPSC). Gynecologic Oncology 92:435-436, 2004.
40. See HT, Walker PW, Palmer JL, Basen-Engquist K, Elsayem A, DeGarcia L, Sun CC, Bodurka DC, Kavanagh JJ. Palliative Care Index for Ovarian Cancer. International Gynecologic Cancer Society:544, 2004.
41. Sun CC, Weaver CB, Fitzgerald MA, Wolf JK, Ramirez PT, Gershenson DM, Bodurka DC. Preferences (PREF) of physicians (MDs) and patients (pts) with ovarian cancer (OVCA): Who values what? . Gynecologic Oncology 92:501, 2004.
42. Frumovitz M, Sun CC, Schover LR, Jhingran A, Eifel PJ, Bevers TB, Levenback C, Bodurka DC. Quality of Life in Cervix Cancer Survivors: Five Years Posttreatment. Gynecologic Oncology 92:474, 2004.
43. Tseng JF, Sun CC, Abdalla EK, Vauthey J, Pisters PW, Lee JE, Evans DB. Resection of the Superior Mesenteric-Portal Vein for Pancreatic Adenocarcinoma: Margin Status and Survival Duration. Gastroenterology 126(4, Suppl.2):A-769, 2004.
44. Schmeler K, Soliman P, Sun C, Oh J, Slomovitz B, Lu K. Risk factors for endometrial cancer in young, premenopausal, non-obese women. poster presentation. Third Annual American Association for Cancer Research International Conference: Frontiers in Cancer Prevention Research, 2004.
45. Soliman PT, Slomovitz BM, Broaddus R, Sun CC, Oh J, Gershenson DM, Lu KH. Synchronous Primary Cancers of the Endometrium and Ovary: A single institution review of 75 cases. Gynecologic Oncology 92:482-483, 2004.
46. Tseng JF, Kronowitz, SJ, Hunt KK, Sun CC, Babiera GV, Singletary E, Mirza NQ, Ames FC, Meric-Bernstam F, Ross MI, Feig BW, Robb GL, Kuerer HM. The Rate of Immediate Reconstruction Following Mastectomy for Breast Cancer Varies by Patient Race. Annals of Surgical Oncology 11(Suppl 2):S32, 2004.
47. Slomovitz BM, Sun CC, Frumovitz M, Soliman PT, Pearson HC, Berenson A, Bodurka DC. Are women ready for the cervical cancer vaccine? . Gynecologic Oncology 96:912, 2005.
48. Slomovitz BM, Ramondetta LM, Crotzer C, Soliman P, Schmeler K, Broaddus RR, Sun CC, Gershenson DM, Burke TW, Lu KL ,. Clinical and pathologic review of clear cell carcinoma of the endometrium: a single institution study of 81 patients. poster presentation. 36th Annual Meeting of the Society of Gynecologic Oncologists:accepted for March 2005, 2005.
49. Lu KH, Schorge J, Rodabaugh K, Sun C, Daniels M, White K, Soliman P, Luthra R, Broaddus R. Defining criteria for Lynch/HNPCC in women under 50 with endometrial cancer: Final results of a prospective, multi-center study. Journal of Clinical Oncology 23(16S):848s, 2005.
50. Schmeler K, Soliman P, Sun C, Oh J, Gershenson D, Slomovitz B, Lu K. Defining endometrial cancer risk factors for young, non-obese women. Gynecologic Oncology 96:1015, 2005.
51. Zighelboim I, Ramirez PT, Sun CC, Frumovitz MM, Jhingran A, Levenback C. Factors That Preclude Resection of Bulky Nodal Metastases in Patients with Cervical Cancer. Gynecologic Oncology 96:989-990, 2005.
52. Slomovitz BM, Coleman RL, Soliman PT, Ramondetta LM, Wolf J, Sun CC, Gershenson DM. Is there a survival difference between clear cell and serous carcinoma of the endometrium? A stage and age-matched cohort study. Journal of Clinical Oncology 23(16S):474s, 2005.
53. Bodurka DC, Sun CC, Weaver CB, Bethancourt DL, Fitzgerald MA, Wolf JK, Gershenson DM, Kavanagh JJ, Munsell MF, Donato ML. Longitudinal assessment of quality of life of patients with ovarian cancer receiving high-dose or conventional-dose chemotherapy. Journal of Clinical Oncology 23(16S):470s, 2005.
54. Slomovitz BM, Burke TW, Soliman PT, Ramondetta LM, Eifel PJ, Jhingran A, Wolf J, Sun CC, Gershenson DM. Patterns of recurrence of uterine papillary serous carcinoma. Gynecologic Oncology 96:947, 2005.
55. Sun CC, Bodurka DC, Weaver CB, Bethancourt DL, Fitzgerald MA, Wolf JK, Gershenson DM, Kavanagh JJ, Munsell MF, Donato ML. Preferences over time of chemo-experienced versus chemo-naïve patients for treatment-related side effects. Journal of Clinical Oncology 23(16S):784s, 2005.
56. Schmeler KM, Soliman PT, Munsell MF, Daniels MS, White KG, Boyd-Rogers SG, Sun CC, Slomovitz BM, Gershenson DM, Lu KH. Prophylactic surgery for the reduction of gynecologic cancer risk in women with Lynch syndrome/HNPCC. Journal of Clinical Oncology 23(16S):844s, 2005.
57. Schmeler K, Sun C, Bodurka DC, White K, Soliman PT, Uyei AR, Erlichman J, Arun B, Peterson S, Milam M, Slomovitz B, Gershenson DM, Lu K. Are women with BRCA1/2 mutations choosing prophylactic bilateral salpingo-oophorectomy over surveillance?. Gynecologic Oncology 101:S107, 2006.
58. Milam M, Slomovitz B, Schmeler K, Soliman PT, Ramirez P, Sun C, Eifel P, Ramondetta L, Lu K. Management and patterns of recurrence of women with occult stage II endometrioid endometrial cancer. Gynecologic Oncology 101:S77, 2006.
59. Soliman PT, Morris V, Sun C, Ramirez P, Weaver C, Jennings J, Schmeler K, Slomovitz B, Bodurka DC. No increase in risk associated with primary surgical cytoreduction in women diagnosed with ovarian cancer at an advanced age. Gynecologic Oncology 101:S143-144, 2006.
60. Schmeler K, Broaddus R, Sun C, Soliman PT, Milam M, Thornton A, Wu W, Slomovitz B, Gershenson D, Lu K, McCampbell A, Shipley G. Obesity-related endometrial cancers are not molecularly distinct from endometrial cancers arising in normal-weight women. Gynecologic Oncology 101:S101-102, 2006.
61. Sun CC, Peterson SK, White KG, Watts BG, Daniels MS, Boyd-Rogers SG, Schmeler KM, Bodurka DC, Lu KH. Preferences for cancer prevention strategies in women with hereditary nonpolyposis colorectal cancer. Journal of Clinical Oncology 24(18S):1018, 2006.
62. Soliman PT, Tortolero-Luna G, Schmeler K, Milam M, Slomovitz B, Sun C, Brown J, Gershenson D, Lu K, Williams M, Betts P. Racial/ethnic differences in survival among Texas women with endometrial cancer: A population-based study. Gynecologic Oncology 101:S80, 2006.
63. Schmeler K, Tortolero-Luna G, Soliman PT, Sun C, Milam M, Slomovitz B, Gershenson D, Lu K, Williams M, Betts P. Racial/ethnic differences in survival among Texas women with ovarian cancer: A population-based study. Gynecologic Oncology 101:S63-64, 2006.
64. Thaker P, Sun C, Bodurka DC, Palmer JL, Pei BL, Willey J, Bruera E, Ramondetta LM. Spirituality and locus of control in a palliative care setting. Gynecologic Oncology 101:S107-108, 2006.
65. Thaker PH, Sun C, Bodurka DC, Palmer J, Pei B, Willey J, Bruera E, Ramondetta L. Spirituality, quality of life, and locus of control in a palliative care setting. Journal of Clinical Oncology 24(18S):690S, 2006.
66. Frumovitz MF, dos Reis R, Sun CC, Milam M, Brown J, Bevers M, Ramirez PT. A Comparison of Total Laparoscopic vs. Abdominal Radical Hysterectomy for Cervical Cancer. Gynecologic Oncology 104(3S1):S25, 2007.
67. Katz, MHG, Wolff RA, Pisters PWT, Sun CC, Evans DB, Varadhachary GR, Fleming JB, Hwang RF. Borderline Resectable Pancreatic Cancer: The Importance of this Emerging Stage of Disease. Accepted for presentation at the 2007 Southern Surgical Association Annual Meeting, 2007.
68. Sun CC, Westin SN, Lu KH, Milam MR, Schmeler KM, White KG, Daniels MS, Arun BK, Peterson SK, Bodurka DC. Impact of BRCA 1/2 Testing: Body Image, Sexual Functioning, and Quality of Life (QOL). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 25(18S):1525, 2007.
69. Westin SN, Sun CC, Lu KH, Milam MR, Schmeler KM, White KG, Daniels MS, Arun BK, Peterson SK, Bodurka DC. Management Strategies for Women at High Risk for Breast and Ovarian Cancer: Are Women Satisfied?. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 25(18S):1524, 2007.
70. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Coleman RL, Ramirez PT, Gershenson DM. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 25(18S):5571, 2007.
71. Milam MR, Sun CC, Landen CN, Schmeler KM, Lu KH, Coleman RL, Ramirez PT. Neoadjuvant Chemotherapy Improves Perioperative Outcomes in Patients with Advanced Epithelial Ovarian Cancer. Gynecologic Oncology 104(3S1):S43, 2007.
72. Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Bodurka DC, Lu KH, Hortobagyi GN, Arun BK. Perception of screening and risk-reduction surgeries in patients tested for a BRCA mutation. Accepted for poster presentation at the 2007 Breast Cancer Symposium, 2007.
73. Burke TW, Navo MA, Smith JA, Jung MS, Broaddus R, Iyer RB, Lu KH, Sun CC, Atkinson EN, Ramondetta LM. Phase II trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma (LGESS). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 25(18S):5595, 2007.
74. Lacour RA, Westin SN, Daniels MS, Milam MR, Sun CC, Urbauer DL, Ramirez PT, Bodurka DC, Gershenson DM, Lu KH. Survival in advanced-stage ovarian cancer patients with non-Ashkenazi Jewish BRCA mutations. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 25(18S):5514, 2007.
75. Frumovitz M, Sun CC, Brown J, dos Reis, R, Milam, M, Levenback CL, Ramirez PT. Total laparoscopic radical hysterectomy in an academic vs community setting. Journal of Minimally Invasive Gynecology 14:48, 2007.
76. Ramondetta L, Johnson A, Sun C, Achanta L, Kavanagh J. A Survey On the Role of Religion and Spirituality in Gynecologic Oncologists. Supportive Care in Cancer 16(6):718, 2008.
77. Bodurka DC, Deavers M, Tian C, Sun CC, Ozols RF, Gershenson DM. Ancillary study of GOG 158: Survival based on reclassification to a two-tier grading system for serous carcinoma of the ovary. Gynecologic Oncology 108(3 Supplement):S33, 2008.
78. Ostler DA, Malpica A, Sun CC, Perna AG, Diwan AH, Lazar AJ, Deavers MT, Prieto VG. Comparative study of methods to determine depth of invasion in vulvar squamous cell carcinoma. Laboratory Investigation 88(Supplement 1s):216A-217A, 2008.
79. Lacour RA, Daniels MS, Westin SN, Meyer LA, Choubey V, Blank SV, MacDonald HR, Roman L, Estes JM, Barnes M, Teoh D, Powell B, Sun CC, Urbauer DL, Ramirez PT, Bodurka DC, Gershenson DM, Lu KH. Do BRCA mutations confer a survival advantage in all cases of advanced-stage ovarian cancer?. Gynecologic Oncology 108(3 Supplement):S108-109, 2008.
80. Meyer LA, Westin SN, Lacour RA, Urbauer DL, Sun CC, Daniels MS, Schmeler KM, Gershenson DM, Lu KH. Evaluating women with ovarian cancer for BRCA 1/2: Missed Opportunities. Gynecologic Oncology 108(3 Supplement):S67-68, 2008.
81. Meyer L, Westin SN, Lacour RA, Urbauer DL, Schmeler KM, Daniels MS, Sun CC, Gershenson DM, Lu KH. Evaluating women with ovarian cancer for BRCA 1/2: missed opportunities. Journal of Clinical Oncology 2008 ASCO Annual Meeting Proceedings Part I 26(15S):300S, 2008.
82. Sun CC, Westin SN, Lacour RA, Meyer LA, Tung CS, Urbauer DL, Frumovitz M, Gershenson DM, Lu KH, Bodurka DC. Health concerns of long-term survivors of gynecologic cancers. Journal of Clinical Oncology 2008 ASCO Annual Meeting Proceedings Part I 26(15S):727S, 2008.
83. Schmeler KM, Jhingran A, Iyer RB, Sun CC, Eifel PJ, Soliman PT, Ramirez PT, Frumovitz MM, Bodurka DC, Sood AK. Pelvic fractures following radiation therapy for cervical cancer: implications for survivors. Journal of Clinical Oncology 2008 ASCO Annual Meeting Proceedings Part I 26(15S):300S, 2008.
84. Sun CC, Aguilliard J, Jhingran A, Eifel P, Crane CH, Phan A, Ramondetta LM, Frumovitz MF, Elting L, Bodurka DC. Preferences for Side Effects of Chemoradiation: Focus on Nausea and Vomiting. Supportive Care in Cancer 16(6):734, 2008.
85. Gershenson DM, Sun C, Bodurka D, Coleman RL, Lu KH, Sood AK, Kavanagh JJ. Recurrent low-grade serous carcinoma of the ovary is relatively chemoresistant. Gynecologic Oncology 108(3 Supplement 1):S5, 2008.
86. Thaker P, Sun CC, Palmer L, Pei BL, Bruera E, Ramondetta L. Spirituality, Coping and Control In a Palliative Care Setting. Supportive Care in Cancer 16(6):719, 2008.
87. Westin SN, Sun CC, Lacour RA, Meyer LA, Tung CS, Urbauer DL, Frumovitz M, Lu KH, Gershenson DM, Bodurka DC. Survivors of gynecologic malignancies (GYN CA): Impact of treatment on health and well-being. Journal of Clinical Oncology 2008 ASCO Annual Meeting Proceedings Part I 26(15S):299S, 2008.
88. Westin SN, Sun CC, Lacour RA, Urbauer DL, Lu KH, Bodurka DC. Survivors of Gynecologic Malignancies (Gyn Ca): Impact of Treatment on Health and Well-being. Supportive Care in Cancer 16(6):752, 2008.
89. Lacour RA, White KG, Daniels MS, Westin SN, Meyer LA, Burke CC, Burns KA, Kurian S, Webb NF, Pustilnik T, Urbauer DL, Sun CC, Bodurka DC, Gershenson DM, Lu KH. What women with ovarian cancer think and know about genetic testing. Gynecologic Oncology 108(3 Supplement):S59, 2008.
90. Sun CC, Peterson S, Lu KH, White K, Daniels M, Boyd-Rogers S, Westin SN, Bodurka DC. Women’s preferences for cancer screening strategies and prophylactic surgery. Gynecologic Oncology 108(3 Supplement):S137, 2008.
91. Tung CS, Sun CC, Cohen L, Frenkel M, Ramondetta LM, Smith JA, Parker P, Bodurka DC. Complementary and alternative medicine: What do oncology healthcare providers think?. Journal of Clinical Oncology 27(suppl):e20614, 2009.
92. Kwon JS, Daniels MS, Sun CC, Lu KH. Opportunities for future cancer prevention by BRCA mutation testing of women with ovarian cancer. Gynecologic Oncology 112(S98), 2009.
93. Sun CC, Ramondetta LM, Jhingran A, Eifel PJ, Crane C, Phan AT, Frumovitz MM, Elting LS, Bodurka DC. Patient preferences for chemoradiation related side effects. Journal of Clinical Oncology 27(suppl):e20604, 2009.
94. Ramondetta LM, Fields MM, Brown J, Rodriquez S, Folloder J, Sun CC. Barriers to Cervical Cancer Screening in Medically Underserved Women: Still More To Be Done. Gynecologic Oncology 113(Issue 3):S39-S40, 3/2010.
95. Schlumbrecht MP, Gallagher CM, Sun CC, Ramondetta LM, Bodurka DC. Ethics Consultation on a Gynecologic Oncology Service: A Learning Opportunity for Physicians. Gynecologic Oncology 116(Issue 3):S57-S58, 3/2010.
96. Daniels MS, Vineyard M, Urbauer D, Deavers M, Sun CC, Boerwinkle E, Bodurka D, Gershenson D, Lu K. Is low grade serous ovarian cancer part of the hereditary breast and ovarian cancer tumor spectrum?. Gynecologic Oncology 116(Issue 3):S98-S99, 3/2010.
97. Westin SN, Sun CC, Schlumbrecht MP, Tung CS, Lacour RA, Meyer LA, Urbauer DL, Soliman PT, Lu KH, Bodurka DC. Persistent obesity among endometrial cancer survivors: A teachable moment?. Gynecologic Oncology 116(Issue 3):S81-S82, 3/2010.
98. Schmeler KM, Tao X, Frumovitz M, Deavers MT, Sun CC, Sood AK, Brown J, Gershenson DM, Ramirez PT. Prevalence of lymph node involvement in primary mucinous carcinoma of the ovary. Gynecologic Oncology 116(Issue 3):S112-S113, 3/2010.
99. Schlumbrecht MP, Sun CC, Wong KN, Broaddus RR, Gershenson DM, Bodurka DC. The Role of Smoking in Low-Grade Serous Ovarian Carcinoma. Gynecologic Oncology 116(Issue 3):S123-S124, 3/2010.
100. Bodurka D, Sun C, Jhingran A, Urbauer D, Levenback C, Eifel P, Ramondetta L, Ramirez P, Frumovitz M, Schover L. A Longitudinal Evaluation of Sexual Functioning and Quality of Life in Cervical Cancer Survivors. Gyncologic Oncology 120(Supplement 1):S81-S82, 2010.
101. Gershenson DM, Sun CC, Malpica A, Deavers M, Bodurka DC, Schmeler KM. Low-grade serous primary peritoneal carcinoma. J Clin Oncol 28(15s) (#5057), 2010.
102. Sun CC, Peterson SK, White KG, Boyd-Rogers S, Schmeler KM, Bodurka DC, Lu KH. Patient preferences for risk management strategies for women with Lynch syndrome. Familial Cancer 9(4):732-733, 2010.
103. Iglesias D, Sun C, Langstraat C, Bakkum-Gamez J, El-Nashar S, Keeler E, Gershenson D, Lu L. Management and clinical outcomes of women with BRCA1/2 mutations found to have occult cancers at the time of risk-reducing salpingo-oophorectomy. Gynecologic Oncology 120(Supplement 1):S59-S60, 3/2011.
104. Pentz RD, Farmer ZL, Green MJ, Daugherty C, Hlubocky FJ, Peterson SK, Sun CC, Lewis CM, Owonikoko TK, Khuri FR and Harvey RD. Assessing patients’ values when standard-of-care options are exhausted. Journal of Clinical Oncology ASCO Annual Meeting Proceedings 29(15_supplement):9108, 5/2011.
105. Huang M, Djordjevic B, Urbauer D, Westin SN, Sun CC, Burzawa JK, Meyer L, Bodurka DC, Broaddus R and Lu KH. Molecular analysis of endometrial pathogenesis in Lynch syndrome. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Proceedings 29(15_supplemental):9108, 5/2011.
106. Schlumbrecht MP, Sun CC, Westin SN, Zandstra F, Denton K, Rhodes H, Gonzales DA, Garcia EA, Levenback CL, Bodurka DC. Lifestyle modification in cervical cancer survivors: an ongoing need. Gyncologic Oncology 120(Supplement 1):S109, 2011.
107. Huang M, Westin SN, Sun CC, Meyer L, Tung C, Urbauer D, Bodurka DC. Menopausal Symptoms and Hormone Replacement Use: The Gynecologic Cancer Survivors’ Perspective. Gynecologic Oncology 120(Supplement 1):S59-S60, 2011.
108. Bodurka DC, Jhingran A, Ramondetta LM, Eifel PJ, Crane CH, Phan AT, Urbauer D, Frumovitz MM, Elting LS, Sun CC. Visual analog scale (VAS) and time trade-off (TTO) preferences for side effects (SE) of chemoradiation (chemoXRT): A comparison of patients (pts) and caregivers (CG). J Clin Oncol 28(15s) (#9056), 2011.
109. Ramondetta LM, Jhingran A, Frumovitz M, Delgado M, Brown J, Eifel P, Palencia J, Sun CC. Protective effects of spirituality and religiosity in underserved women with cervical cancer (CXCA). Support Care Cancer 19(Suppl 2):S67-S370, 2011.

Book Chapters

1. Bodurka DC, Sun CC, Basen-Engquist KM. Quality of Life in the Gynecologic Cancer Patient. In: Gynecologic Cancer: Controversies in Management. Elsevier Ltd, 785-794, 2004.
2. Bodurka DC Sun CC. Quality of Life and Sexual Functioning. In: Gynecologic Cancer, in press, 2000.
3. Rubenstein EB Sun CC. Outpatient Management of Chemotherapy-Treated Patients. In: Supportive Care in Cancer: A Handbook for Oncologists. Marcel Dekker, Inc., 1998.
4. Rubenstein EB, Elting LS, Sun CC, Rolston KVI. Outpatient Management of Neutropenic Fever: Antibiotics, Growth Factors or Both? . In: Clinical Applications of Cytokines and Growth Factors. Kluwer Academic Publishers, 1998.

Manuals, Teaching Aids, Other Teaching Publications

1. Sun CC. Helping Cancer Patients with Quality of Life Treatment Decisions. 2005.
2. Sun CC. Ovarian Cancer: Quality of Life Issues, National Ovarian Cancer Coalition. 2005.

Grant & Contract Support

Title: Optimizing Treatment of Rectal Cancer Using as Markov Decision Model
Funding Source: NIH/NCI
Role: Consultant
Principal Investigator: George J Chang
Duration: 2009 - 2014
 
Title: Integrating Patients' Values Into Decisions to Enroll in Phase I Oncology Trials
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Rebecca D. Pentz, PhD
Duration: 2009
 
Title: Evalution and Mitigation of Potential Harms Associated with Virtual Colonscopy
Funding Source: NIH/NCI
Role: Consultant
Principal Investigator: David Vining, MD
Duration: 2009
 
Title: A Review of services Used by Gynecologic Cancer Survivors
Funding Source: MDACC Holiday Letter Program
Role: Principal Investigator
Duration: 2008 - 2009
 
Title: Chemoradiation-Induced Nausea and Emesis: A Prospective Study to Assess Patient Preferences and Quality of Life
Funding Source: Merck & Co.
Role: Principal Investigator
Duration: 1/1/2003 - 1/1/2005
 
Title: Preferences, Quality of Life, and Symptom Assessment of Ovarian Cancer Patients Enrolled on a Randomized Trial of High-Dose versus Conventional Dose Chemotherapy
Funding Source: Blanton-Davis Ovarian Cancer Research Program
Role: Principal Investigator
Duration: 1/1/2003 - 1/1/2004
 
Title: Sexual Functioning and Quality Of Life in Women with Cervical Cancer
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Principal Investigator: Diane Bodurka, M.D.
Duration: 1/1/2002 - 1/1/2004
 
Title: Evaluating Patient Preferences, Quality of Life and Symptoms of Treatment in Ovarian Cancer Patients Receiving High-Dose and Standard Chemotherapy
Funding Source: The University of Texas M. D. Anderson Cancer Center
Role: Collaborator
Principal Investigator: Principal Investigator: Diane Bodurka-Bevers, M.D.
Duration: 1/1/2000 - 1/1/2002
 
Title: Unrestricted grant from Merck & Co. to conduct patient preferences and quality of life research
Funding Source: Merck & Co.
Role: Collaborator
Duration: 1/1/2000
 
Title: Prophylactic Oophorectomy and Mastectomy for Women at Risk of Breast and Ovarian Incorporating Preferences in a Decision Analysis,”
Funding Source: The University of Texas M. D. Anderson Cancer Center
Role: Collaborator
Principal Investigator: Principal Investigator: Diane Bodurka-Bevers, M.D.
Duration: 1/1/1997 - 1/1/1999

Last updated: 8/14/2013